Veracyte Presents New Data Findings Are From The Prospective, Multicenter VANDAAM Trial, Show That Its Decipher Prostate Test Predicts Aggressive Prostate Cancer In African American Men At ASTRO 2024
Veracyte Presents New Data Findings Are From The Prospective, Multicenter VANDAAM Trial, Show That Its Decipher Prostate Test Predicts Aggressive Prostate Cancer In African American Men At ASTRO 2024
Findings are from the prospective, multicenter VANDAAM trial
这些发现来自前瞻性、多中心的VANDAAm试验。
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease. The findings confirm that the market-leading genomic test offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions for African American men, a population that is disproportionately impacted by the disease. The new data were shared today in an oral presentation at ASTRO 2024, the annual meeting of the American Society for Radiation Oncology, in Washington, D.C.
领先的癌症诊断公司Veracyte, Inc.（纳斯达克: VCYT）宣布，来自多中心、前瞻性VANDAAm试验的新数据显示，Decipher前列腺基因分类器可以准确预测早期疾病中非洲裔美国男性患有侵袭性前列腺癌的风险。这些发现证实了这一市场领先的基因测试为临床医生在指导非洲裔美国男性的前列腺癌治疗决策方面比单纯依靠临床因素有所改进，而这一人群所受疾病影响显著。新数据今天在美国放射肿瘤学会（ASTRO）2024年年会上以口头报告形式分享，在华盛顿特区举行。
African American men are more than 70% as likely to be diagnosed with prostate cancer and more than twice as likely to die of the disease, compared to white men, according to the American Cancer Society.1 Despite this, few prospective studies have specifically sought to examine the disease at a genomic level in this population.
根据美国癌症协会的数据，与白人男性相比，非洲裔美国男性被诊断患有前列腺癌的概率高出70%以上，死于该疾病的概率是白人男性的两倍以上。尽管如此，仍然很少有前瞻性研究专门探讨了在该人群中对该疾病进行基因组水平的研究。
